4D Molecular Therapeutics FDMT Change in Lease Liabilities
Change in Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's change in lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's change in lease liabilities?
- 4D Molecular Therapeutics (FDMT) reported change in lease liabilities of -$878K in Q1 2026.
- How has 4D Molecular Therapeutics's change in lease liabilities changed year-over-year?
- 4D Molecular Therapeutics's change in lease liabilities decreased by 16.4% year-over-year, from -$754K to -$878K.
- What is the long-term trend for 4D Molecular Therapeutics's change in lease liabilities?
- Over 3 years (2022 to 2025), 4D Molecular Therapeutics's change in lease liabilities has grown at a 114.4% compound annual growth rate (CAGR), from -$324K to -$3.19M.
- What does change in lease liabilities mean?
- Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.